JP2949448B2
(ja)
*
|
1992-11-30 |
1999-09-13 |
ケーヴィ ファーマセチカル カンパニー |
味を隠された医薬材料
|
DK0744941T3
(da)
*
|
1994-02-16 |
2003-09-29 |
Abbott Lab |
Fremgangsmåde til fremstilling af findelte farmaceutiske formuleringer
|
US5728403A
(en)
*
|
1994-10-05 |
1998-03-17 |
The Board Of Regents Of The University Of Nebraska |
Coating technology for taste masking orally administered bitter drugs
|
DE29502547U1
(de)
*
|
1995-02-16 |
1995-03-30 |
Roehm Gmbh |
Thermoplastisches Überzugs- und Bindemittel für Arzneiformen
|
ATE352289T1
(de)
*
|
1995-05-02 |
2007-02-15 |
Taisho Pharmaceutical Co Ltd |
Mittel zur oralen verabreichung
|
AUPO637197A0
(en)
*
|
1997-04-23 |
1997-05-15 |
F.H. Faulding & Co. Limited |
Taste-masked pharmaceutical compositions
|
DE19617487A1
(de)
†
|
1996-05-02 |
1997-11-06 |
Merck Patent Gmbh |
Geschmacksverbesserung von Arzneimittelwirkstoffen
|
AUPN969796A0
(en)
*
|
1996-05-07 |
1996-05-30 |
F.H. Faulding & Co. Limited |
Taste masked liquid suspensions
|
DE19706979A1
(de)
*
|
1997-02-21 |
1998-08-27 |
Lindopharm Gmbh |
Kombinationspräparat für oral applizierbare Erythromycine
|
DE19706978A1
(de)
*
|
1997-02-21 |
1998-08-27 |
Ulrich Dr Posanski |
Kombinationspräparat für oral applizierbare Antibiotika
|
US6010718A
(en)
*
|
1997-04-11 |
2000-01-04 |
Abbott Laboratories |
Extended release formulations of erythromycin derivatives
|
US6551616B1
(en)
*
|
1997-04-11 |
2003-04-22 |
Abbott Laboratories |
Extended release formulations of erythromycin derivatives
|
US20050064033A1
(en)
*
|
1997-04-11 |
2005-03-24 |
Notario Gerard F. |
Extended release formulations of erythromycin derivatives
|
US6861411B1
(en)
*
|
1997-12-02 |
2005-03-01 |
Pfizer, Inc. |
Method of treating eye infections with azithromycin
|
KR100514330B1
(ko)
*
|
1997-12-31 |
2006-02-17 |
주식회사 중외제약 |
난용성 약물을 함유하는 코팅정
|
US7122207B2
(en)
*
|
1998-05-22 |
2006-10-17 |
Bristol-Myers Squibb Company |
High drug load acid labile pharmaceutical composition
|
JP3466921B2
(ja)
*
|
1998-06-03 |
2003-11-17 |
大塚製薬株式会社 |
味マスキング医薬製剤
|
WO2000018372A1
(fr)
*
|
1998-09-30 |
2000-04-06 |
Taisho Pharmaceutical Co., Ltd. |
Granules pour preparations orales
|
EP1027885B1
(en)
*
|
1999-02-09 |
2008-07-09 |
Pfizer Products Inc. |
Basic drug compositions with enhanced bioavailability
|
DE19907895A1
(de)
*
|
1999-02-24 |
2000-11-16 |
Paz Arzneimittelentwicklung |
Verwendung von R-Arylpropionsäuren zur Herstellung von Arzneimitteln zur Behandlung von Erkrankungen bei Mensch und Tier, welche durch die Hemmung der Aktivierung von NF-kB therapeutisch beeinflußt werden können
|
CN1343128B
(zh)
*
|
1999-03-17 |
2010-04-21 |
第一制药株式会社 |
药物组合物
|
SI20244A
(sl)
*
|
1999-05-19 |
2000-12-31 |
LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. |
Granulacija v talini
|
IN191239B
(no)
|
1999-06-11 |
2003-10-11 |
Ranbaxy Lab Ltd |
|
US6565882B2
(en)
*
|
2000-02-24 |
2003-05-20 |
Advancis Pharmaceutical Corp |
Antibiotic composition with inhibitor
|
US6544555B2
(en)
|
2000-02-24 |
2003-04-08 |
Advancis Pharmaceutical Corp. |
Antibiotic product, use and formulation thereof
|
EP1313486A1
(en)
*
|
2000-02-29 |
2003-05-28 |
Teva Pharmaceutical Industries Ltd. |
Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
|
MXPA02009587A
(es)
*
|
2000-03-28 |
2003-05-14 |
Biochemie Gmbh |
Particulas granuladas con sabor enmascarado.
|
US6551617B1
(en)
|
2000-04-20 |
2003-04-22 |
Bristol-Myers Squibb Company |
Taste masking coating composition
|
DE60128215T2
(de)
|
2000-04-20 |
2008-01-10 |
Novartis Ag |
Beschichtungszusammensetzung zur geschmacksmaskierung
|
AU2001275043A1
(en)
|
2000-05-31 |
2001-12-11 |
Drugtech Corporation |
Mineral supplement
|
AU6068001A
(en)
*
|
2000-06-01 |
2001-12-11 |
Taisho Pharmaceutical Co., Ltd. |
Matrices for oral preparations
|
HUP0303700A3
(en)
*
|
2000-07-17 |
2006-07-28 |
Astellas Pharma Inc Chuo Ku |
Pharmaceutical composition improved in peroral absorbability
|
WO2002024167A1
(fr)
*
|
2000-09-19 |
2002-03-28 |
Daiichi Pharmaceutical Co., Ltd. |
Composition medicinale
|
AU2001294192A1
(en)
|
2000-10-06 |
2002-04-22 |
Takeda Chemical Industries Ltd. |
Solid preparations
|
CA2425688A1
(en)
*
|
2000-10-13 |
2002-05-16 |
Donald J. Treacy Jr. |
Extended release erythromycin derivatives
|
US20020068078A1
(en)
*
|
2000-10-13 |
2002-06-06 |
Rudnic Edward M. |
Antifungal product, use and formulation thereof
|
JP4706096B2
(ja)
*
|
2000-10-23 |
2011-06-22 |
大正製薬株式会社 |
不快な味を呈する塩基性薬物配合製剤
|
AU2002224053A1
(en)
*
|
2000-11-21 |
2002-06-03 |
Kyorin Pharmaceutical Co. Ltd. |
Dry syrup preparations
|
US20020197314A1
(en)
*
|
2001-02-23 |
2002-12-26 |
Rudnic Edward M. |
Anti-fungal composition
|
MY129350A
(en)
*
|
2001-04-25 |
2007-03-30 |
Bristol Myers Squibb Co |
Aripiprazole oral solution
|
DK1411899T3
(da)
*
|
2001-08-01 |
2009-06-02 |
Novartis Ag |
Smagsmaskerende sammensætning
|
EP1920766B1
(en)
|
2002-02-01 |
2017-08-23 |
Bend Research, Inc |
Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
|
KR20040083493A
(ko)
|
2002-02-01 |
2004-10-02 |
화이자 프로덕츠 인크. |
콜레스테릴 에스테르 전달 단백질 억제제의 제어 방출형제약상 제형
|
AR038375A1
(es)
|
2002-02-01 |
2005-01-12 |
Pfizer Prod Inc |
Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
|
US20040043073A1
(en)
*
|
2002-06-14 |
2004-03-04 |
Chih-Ming Chen |
Pharmaceutical compositions for drugs having pH-dependent solubility
|
ES2333318T3
(es)
|
2002-08-12 |
2010-02-19 |
Bend Research, Inc. |
Composiciones farmaceuticas de medicamentos con estructura semiordenada y de polimero.
|
DE60323536D1
(de)
|
2002-12-20 |
2008-10-23 |
Pfizer Prod Inc |
Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
|
US20040146553A1
(en)
*
|
2002-12-23 |
2004-07-29 |
Aventis Pharma S.A. |
Compositions for oral administration of active principles requiring masking of taste
|
KR100508992B1
(ko)
*
|
2003-03-31 |
2005-08-17 |
한국유나이티드제약 주식회사 |
쓴 맛을 개선한 클래리스로마이신 경구용 약제 조성물 및 그의 제조 방법
|
WO2005009365A2
(en)
*
|
2003-07-21 |
2005-02-03 |
Advancis Pharmaceutical Corporation |
Antibiotic product, use and formulation thereof
|
WO2005009368A2
(en)
*
|
2003-07-21 |
2005-02-03 |
Advancis Pharmaceutical Corporation |
Antibiotic product, use and formulation thereof
|
JP2006528185A
(ja)
*
|
2003-07-21 |
2006-12-14 |
アドバンシス ファーマスーティカル コーポレイション |
抗生物質製剤、その使用法及び作成方法
|
US8758820B2
(en)
|
2003-08-11 |
2014-06-24 |
Shionogi Inc. |
Robust pellet
|
CA2535398C
(en)
|
2003-08-12 |
2013-11-12 |
Advancis Pharmaceuticals Corporation |
Antibiotic product, use and formulation thereof
|
AU2004270170B2
(en)
*
|
2003-08-29 |
2011-01-27 |
Shionogi, Inc. |
Antibiotic product, use and formulation thereof
|
US7282217B1
(en)
|
2003-08-29 |
2007-10-16 |
Kv Pharmaceutical Company |
Rapidly disintegrable tablets
|
CA2538064C
(en)
*
|
2003-09-15 |
2013-12-17 |
Advancis Pharmaceutical Corporation |
Antibiotic product, use and formulation thereof
|
US20080293801A1
(en)
*
|
2003-11-14 |
2008-11-27 |
Pfizer Inc. |
Solid Amorphous Dispersions of An Mtp Inhibitor For Treatment of Obesity
|
JP2007513146A
(ja)
*
|
2003-12-04 |
2007-05-24 |
ファイザー・プロダクツ・インク |
液体系プロセスによるアジスロマイシンマルチパーティキュレート剤形
|
BRPI0417360A
(pt)
*
|
2003-12-04 |
2007-03-13 |
Pfizer Prod Inc |
método para a preparação de multiparticulados farmacêuticos
|
WO2005053639A2
(en)
*
|
2003-12-04 |
2005-06-16 |
Pfizer Products Inc. |
Controlled release multiparticulates formed with dissolution enhancers
|
KR20060109481A
(ko)
*
|
2003-12-04 |
2006-10-20 |
화이자 프로덕츠 인코포레이티드 |
바람직하게는 폴록사머와 글리세라이드를 함유하는다미립자 아지트로마이신 조성물의 제조를 위해 압출기를사용하는 분무응결 방법
|
US6984403B2
(en)
*
|
2003-12-04 |
2006-01-10 |
Pfizer Inc. |
Azithromycin dosage forms with reduced side effects
|
WO2005053652A1
(en)
|
2003-12-04 |
2005-06-16 |
Pfizer Products Inc. |
Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
|
BRPI0417348A
(pt)
*
|
2003-12-04 |
2007-03-13 |
Pfizer Prod Inc |
processo de gelatinização por spray com utilização de uma extrusora para preparação de composições de droga cristalina multiparticulada contendo preferencialmente um poloxámero e um glicerìdeo
|
EP1691786A1
(en)
*
|
2003-12-04 |
2006-08-23 |
Pfizer Products Inc. |
Multiparticulate compositions with improved stability
|
WO2005056542A1
(en)
*
|
2003-12-09 |
2005-06-23 |
Pfizer Inc. |
Compositions comprising an hiv protease inhibitor
|
US7943585B2
(en)
|
2003-12-22 |
2011-05-17 |
Sandoz, Inc. |
Extended release antibiotic composition
|
CA2550983C
(en)
*
|
2003-12-24 |
2013-09-17 |
Advancis Pharmaceutical Corporation |
Enhanced absorption of modified release dosage forms
|
EA010888B1
(ru)
|
2004-05-25 |
2008-12-30 |
Пфайзер Продактс, Инк. |
Тетраазабензо[е]азуленовые производные и их аналоги
|
CN1960716B
(zh)
*
|
2004-06-03 |
2011-02-09 |
大正制药株式会社 |
口服制剂及其制造方法
|
AU2005269981A1
(en)
*
|
2004-07-02 |
2006-02-09 |
Bonck, John A |
Tablet for pulsed delivery
|
WO2006082518A1
(en)
|
2005-02-03 |
2006-08-10 |
Pfizer Products Inc. |
Pharmaceutical compositions with enhanced performance
|
US8778924B2
(en)
*
|
2006-12-04 |
2014-07-15 |
Shionogi Inc. |
Modified release amoxicillin products
|
US8357394B2
(en)
|
2005-12-08 |
2013-01-22 |
Shionogi Inc. |
Compositions and methods for improved efficacy of penicillin-type antibiotics
|
US8299052B2
(en)
|
2006-05-05 |
2012-10-30 |
Shionogi Inc. |
Pharmaceutical compositions and methods for improved bacterial eradication
|
US7638541B2
(en)
|
2006-12-28 |
2009-12-29 |
Metabolex Inc. |
5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
|
EP2185544B1
(en)
*
|
2007-07-19 |
2014-11-26 |
Cymabay Therapeutics, Inc. |
N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the rup3 or gpr119 for the treatment of diabetes and metabolic disorders
|
WO2009085637A1
(en)
*
|
2007-12-21 |
2009-07-09 |
Url Pharma, Inc. |
Amorphous metaxalone and amorphous dispersions thereof
|
TW201002705A
(en)
*
|
2008-03-31 |
2010-01-16 |
Metabolex Inc |
Oxymethylene aryl compounds and uses thereof
|
US20110160222A1
(en)
*
|
2008-11-26 |
2011-06-30 |
Metabolex, Inc. |
Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
|
WO2010067233A1
(en)
|
2008-12-08 |
2010-06-17 |
Pfizer Inc. |
1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir)
|
DE102009019268A1
(de)
*
|
2009-04-28 |
2010-11-11 |
Lts Lohmann Therapie-Systeme Ag |
Arzneimittel mit poröser Matrix
|
PL2442791T3
(pl)
|
2009-06-16 |
2020-05-18 |
Pfizer Inc. |
Postacie dawkowania apiksabanu
|
JP5909185B2
(ja)
|
2009-10-01 |
2016-04-26 |
シマベイ セラピューティクス, インコーポレーテッド |
置換テトラゾール−1−イルフェノキシメチルチアゾール−2−イルピペリジニルピリミジン塩
|
JP2013528172A
(ja)
|
2010-05-21 |
2013-07-08 |
ファイザー・インク |
2−フェニルベンゾイルアミド
|
WO2011163090A1
(en)
|
2010-06-23 |
2011-12-29 |
Metabolex, Inc. |
Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
|
LT3119757T
(lt)
|
2014-03-17 |
2018-07-10 |
Pfizer Inc. |
Diacilglicerolio aciltransferazės 2 inhibitoriai, skirti panaudoti metabolinių ir susijusių ligų gydyme
|
WO2017004398A1
(en)
*
|
2015-06-30 |
2017-01-05 |
Kemin Industries, Inc. |
Encapsulated active ingredients for controlled enteric release
|
CN109862896A
(zh)
|
2016-08-03 |
2019-06-07 |
西玛贝医药公司 |
用于治疗炎症性胃肠疾病或胃肠病症的氧亚甲基芳基化合物
|
AR109179A1
(es)
|
2016-08-19 |
2018-11-07 |
Pfizer |
Inhibidores de diacilglicerol aciltransferasa 2
|
CA3056030A1
(en)
|
2017-03-10 |
2018-09-13 |
Pfizer Inc. |
Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors
|
SG11202101503RA
(en)
|
2018-08-31 |
2021-03-30 |
Pfizer |
Combinations for treatment of nash/nafld and related diseases
|
AU2020260018A1
(en)
|
2019-04-19 |
2021-11-04 |
Pfizer Inc. |
Anti-proliferative agents for treating PAH
|
US20220387402A1
(en)
|
2019-05-20 |
2022-12-08 |
Pfizer Inc. |
Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
|
EP3990452A1
(en)
|
2019-06-28 |
2022-05-04 |
Pfizer Inc. |
5-(thiophen-2-yl)-1h-tetrazole derivatives as bckdk inhibitors useful for treating various diseases
|
TW202115086A
(zh)
|
2019-06-28 |
2021-04-16 |
美商輝瑞大藥廠 |
Bckdk抑制劑
|
TWI771766B
(zh)
|
2019-10-04 |
2022-07-21 |
美商輝瑞股份有限公司 |
二醯基甘油醯基轉移酶2 抑制劑
|
JP2022058085A
(ja)
|
2020-02-24 |
2022-04-11 |
ファイザー・インク |
ジアシルグリセロールアシルトランスフェラーゼ2阻害剤とアセチル-CoAカルボキシラーゼ阻害剤との組合せ
|
JP2021134211A
(ja)
|
2020-02-24 |
2021-09-13 |
ファイザー・インク |
Nafld/nashおよび関連疾患の処置のための組合せ
|
JP7487290B2
(ja)
*
|
2020-03-11 |
2024-05-20 |
沢井製薬株式会社 |
顆粒及びそれを用いた製剤
|
IL298891A
(en)
|
2020-06-09 |
2023-02-01 |
Pfizer |
Melanocortin 4 antagonists and use of preparations containing them
|
WO2023100061A1
(en)
|
2021-12-01 |
2023-06-08 |
Pfizer Inc. |
3-phenyl-1-benzothiophene-2-carboxylic acid derivatives as branched-chain alpha keto acid dehydrogenase kinase inhibitors for the treatment of diabetes, kidney diseases, nash and heart failure
|
WO2023105387A1
(en)
|
2021-12-06 |
2023-06-15 |
Pfizer Inc. |
Melanocortin 4 receptor antagonists and uses thereof
|
WO2024075051A1
(en)
|
2022-10-07 |
2024-04-11 |
Pfizer Inc. |
Hsd17b13 inhibitors and/or degraders
|
WO2024084363A1
(en)
|
2022-10-18 |
2024-04-25 |
Pfizer Inc. |
Use of patatin-like phospholipase domain-containing protein 3 compounds
|
WO2024084360A1
(en)
|
2022-10-18 |
2024-04-25 |
Pfizer Inc. |
Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers
|
WO2024084390A1
(en)
|
2022-10-18 |
2024-04-25 |
Pfizer Inc. |
Compounds for the activation of ampk
|